Roche Holding AG Stock News

Vabysmo and Phesgo are still strong growth drivers for the company going forward, growing year over year in Q1 of 2024 by 108% and 70%, respectively. Mid-single digit sales growth is expected to remai

Roche Holding AG (OTCQX:RHHBY) Q1 2024 Sales/ Trading Statement Conference Call April 24, 2024 8:00 AM ET Company Participants Thomas Schinecker - Chief Executive Officer, Roche Group Alan Hippe - Chi

Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.

Swiss pharmaceutical giant Roche on Wednesday said falling sales of COVID-19 tests and medicines will stop having a “material impact” on its business after the first quarter of 2024 following the

Roche lowered its 2024 growth outlook in February as it continues to confront a drop-off in demand for its Covid-19 products and a number of its cancer drugs.

Roche said on Wednesday its first-quarter sales slipped 6% as the loss on COVID-19 related revenue was partly offset by further gains in eye drug Vabysmo.

Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.

Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.

David Roche, president and global strategist at Independent Strategy, discusses Iran's drone and missile attack on Israel and says "you have all degrees of escalation that are possible, but escalation

A Roche-Lilly collaboration to test for indications of Alzheimer's disease won FDA Breakthrough Device Designation on Thursday. The new test will now proceed to clinical trials needed for full FDA app

The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.

Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss three buys and a bail, including Roche, TotalEnergies, AB InBev, and Arm.

Euan Munro of Newton Investment and David Roche of Independent Strategy discuss the possibility of the Federal Reserve reducing interest rates against the backdrop of high government spending and budg

Prescription weight loss drugs, like GLP-1 agonists and orlistat, offer effectiveness for some individuals and have proven effects the market has taken notice of. These drugs focus on curbing appetite

David Roche, president and global strategist at Independent Strategy, says China may be stagnating, but it's "stagnating at a later stage of development than India."